Value proposition

Our mission is to arrest the progression of degenerative diseases driven by mitochondrial dysfunction

MitoRx Therapeutics is a pre-clinical stage rare disease biotech company aiming to become the leading global developer of medicines arresting the progression of degenerative diseases driven by mitochondrial dysfunction, with a focus on neuromuscular disease, metabolic disease and neurodegenerative disease.

mitochondrial disease, rare disease, Duchenne, neuromuscular disease, DMD, biotech, preclinical, drug discovery, mitochondria, new class, MitoRx, MTRX-1, hyperhomocysteinemia, Huntington's, mitochondrial myopathy, muscular dystrophy, neurodegenerative disease, dementia, Huntington's disease, CBS-deficiency, muscular dystrophy, first-in-class, and first-in-target